No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CVAC240816C4000
- 0.40
- -0.07-14.89%
15min DelayTrading Jul 22 12:57 ET
0.40High0.15Low
0.40Open0.47Pre Close71 Volume415 Open Interest4.00Strike Price2.55KTurnover121.60%IV17.96%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.4819Delta0.3325Gamma9.33Leverage Ratio-0.0097Theta0.0010Rho4.49Eff Leverage0.0039Vega
Intraday
- 5D
- Daily
News
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
CureVac CVAC GSK Deal and Restructuring; Scilex SCLX Letter of Intent DECA
Express News | CureVac NV: UK Trial on Validity of Intellectual Property Rights Ep 3 708 668 B1 and Ep 4 023 755 B1 Began July 10; Judgement Expected Later in 2024
Express News | CureVac NV - New Trial Date for U.S. Patent Litigation Set for March 3, 2025, Following Settlement With Acuitas Therapeutics
CureVac: A Buy Rating Amidst Intellectual Property Litigation and Strong Valuation Metrics
CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)
Comments
$CureVac(CVAC.US$ CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
1
$CureVac(CVAC.US$ Good news and people still sell wtf lol
1
$CureVac(CVAC.US$ It's going up up up today the volume already almost as much as it was pre-market yesterday.After Novavax deal they rocketed!
Read more